Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study

@inproceedings{Zsros2013DosedenseCC,
  title={Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study},
  author={J{\'o}zsef Zs{\'i}ros and Laurence Brugi{\`e}res and Penelope R. Brock and Derek J. Roebuck and Rudolf Maibach and Arthur Zimmermann and Margaret H. Childs and Dani{\`e}le M. Pariente and V{\'e}ronique Laithier and J. B. Otte and Sophie Branchereau and Daniel C. Aronson and Arun A. Rangaswami and Milind D. Ronghe and Michela Casanova and Michael V. Sullivan and Bruce Morland and Piotr Czauderna and Giorgio Perilongo},
  booktitle={The Lancet. Oncology},
  year={2013}
}
BACKGROUND The objective of this study was to establish the efficacy and safety of a new treatment regimen consisting of dose-dense cisplatin-based chemotherapy and radical surgery in children with high-risk hepatoblastoma. METHODS SIOPEL-4 was a prospective single-arm feasibility study. Patients aged 18 years or younger with newly diagnosed hepatoblastoma with either metastatic disease, tumour in all liver segments, abdominal extrahepatic disease, major vascular invasion, low α fetoprotein… CONTINUE READING